Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells
Year: 2019
Type: article
Abstract: This study investigated the cytotoxic effects of gemcitabine-loaded solid lipid nanoparticle (Gem-SLN) on the patient-derived primary pancreatic cancer cell lines (PPCL-46) and MiaPaCa-2 pancreatic cancer cells. Different SLN formulations were prepared from glyceryl monostearate (GMS), polysorbate 80 (Tween® 80) and poloxamer 188 (Pol 188) as surfactants using a cold homogenization method. Gem-SLN was characterized for particle size and charge distribution, entrapment efficiency and loading capacity. Fourier Transform Infra-Red (FTIR) spectroscopy was used to verify Gem and SLN interaction while differential scanning calorimetry (DSC) was used to acquire thermodynamic information on Gem-SLN. Cytotoxicity studies was conducted on PPCL-46 cells and Mia-PaCa-2 cells. Among the different Gem-SLN formulations prepared, Gem-SLN 15 was selected based on entrapment efficiency (EE) of Gem, loading efficiency of Gem, cytotoxicity and rate of Gem release. Cytotoxic effect of Gem-SLN 15 -treated PPCL-46 culture (IC 50 (2D) = 27 ± 5 μM; IC 50 (3D) = 66 ± 2 μM) was remarkably higher than gemcitabine hydrochloride (GemHCl)-treated PPCL-46 culture (IC 50 (2D) = 126 ± 3 μM; IC 50 (3D) = 241 ± 3 μM). Similar trend of higher Gem-SLN 15 inhibition in MiaPaCa-2 culture was found (IC 50 (2D) = 56 ± 16 μM; IC 50 (3D) = 127 ± 4 μM) compared with GemHCl-treated Mia-PaCa-2 culture (IC 50 (2D) = 188 ± 46 μM; IC 50 (3D) = 254 ± 52 μM). Overall, Gem-SLN 15 proved to be more effective against PPCL_46 and Mia-PaCa-2 cells than GemHCl treated PPCL-46 and Mia-PaCa-2 cancer cells.
Authors: Kevin O. Affram, Taylor Smith, Edward Ofori, Sunil Krishnan, Patrick Underwood, Jose G. Trevino, Edward Agyare
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Open Access status: hybrid
Estimated APC paid: $3,000
Awards: G2304360047, G2625309460, G3729125859, G5030256445, (1 of 2) Florida Minority Cancer Research & Training Center: Feasibility Studies, G9000014455, 2/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Center, 3/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Center
OpenAlex ID: W2985883253
